Prevnos Information

Prevnos is a biotechnology company operating within the in vitro diagnostics sector. Prevnos engages within the cancer genetics and cytogenetics space, creating novel fluorescence in situ hybridization (FISH) assays for clinical and research use. As the inventors of the world's first Hybrid Fusion FISH™ tests for cancer genetics and diagnostics, Prevnos enables 90%+ efficiency in FISH testing while reducing the overall economic burden for such tests. Prevnos is also the inventor of the Retina Microscope™, the world's most economical and first fluorescence scope to use transparent OLED displays and foil-glass projection displays operating through a thin-client PC, conveniently and optimally suited for a FISH dark room. It is the first FISH scope in its class. Our mission is to make preventive healthcare a priority through early detection and active surveillance via simple and cost-effective screening tools. Prevnos uses "colored dots" (DOT™ - Dynamic Optical Transmission) to identify cancer genes for disease stratification. These colored dots are quantifiable, with specific signal patterns indicating the stage of the disease (i.e. aggressive vs. indolent, benign vs. metastasis). Such actionable information can also be tethered to clinical utility (i.e. ALK FISH for FDA-approved Xalkori). Prevnos' Hybrid Fusion FISH™ tests allow for controlled outcomes to select appropriate and tailored treatment options. Prevnos has characterized 100+ "colored dots" (Hybrid Fusion FISH™ tests) that are implicated in multiple cancers and has created specific panels for each disease. Prevnos also utilizes it's Hybrid Fusion FISH™ technology for operations within the energy sector in the industrial oil fracking industry to increase the efficiency of natural gas collection and purification.